FPH - Fisher Paykel Healthcare.

[kiora]

FPH is not a TRA which needs to be valued on price earning ratios ...it has very valuable IPs and very wide moat ...that part gives it assured value thus unimaginable P/E ratios ...But whom I telling ...U know all this stuff better then me ...master W69 ....:p

And prepared to protect its IP by putting its money were its mouth is
From 2019
"Fisher & Paykel settles all patent litigation with ResMed'
https://www.rnz.co.nz/news/business/383012/fisher-and-paykel-settles-all-patent-litigation-with-resmed

[winner69]

Got excited this morning as it seemed FPH share price was going to rocket past 30 bucks ….but then ASX opened

Tomorrow maybe

Only a month late …. Over 30 bucks it has gone

Cool

[alokdhir]

Only a month late …. Over 30 bucks it has gone

Cool

R the grapes sour mate ? lol :p

[winner69]

FPH share price on a roll ….over 31 bucks

Going great guns ….cool stuff

[kiora]

FPH share price on a roll ….over 31 bucks

Going great guns ….cool stuff

Did you get those ones at $20/share?

[winner69]

Did you get those ones at $20/share?

From low 20’s

Alokdhir kept encouraging me to keep with when the rise slowed down a few times

[kiora]

From low 20’s

Alokdhir kept encouraging me to keep with when the rise slowed down a few times

Well done!.I new you could do it !
Couta would be happy too?

[alokdhir]

From low 20’s

Alokdhir kept encouraging me to keep with when the rise slowed down a few times

Is there anything u miss mate ? FPH @ 20 ...MFT @ 55 and what else ...maybe that's why U envy Fisher fund managers and their pay packets ...lol

I also encouraged u and still doing for KFL ...but u still resisting maybe !!!

[winner69]

Well done!.I new you could do it !
Couta would be happy too?


Getting extremely overvalued in my opinion but heck its a big blue chip so no worries

But need to keep an eye on that squiggly line on the chart

[winner69]

Crickey, RMD down 15% today

Apparently Eli Lilly posted a rave about their GLP drugs for sleep apnoea

Hope FPH don’t go down 15% …might need to lighten up just in case

[kiora]

For those investors that are worrying about weight loss drugs impacting sales.
With all the news about them it has lead to an increase in health consultations.These lead to health programmes that also include treatment for obstructive sleep apnea.
The overall affect for FPH sleep apnea products:Positive


https://www.pewresearch.org/science/2024/02/26/how-americans-view-weight-loss-drugs-and-their-potential-impact-on-obesity-in-the-u-s/

[kiora]

"So what we're hearing back from the sleep practitioners, and the weight loss practitioners, is that CPAP - which is the treatment that ResMed put forward to sleep apnea - is still the primary solution for sleep apnea. The other thing we're observing is that GLP-1s, if anything, are just increasing the treatment awareness for sleep apnea. "
https://www.livewiremarkets.com/wires/buy-hold-sell-2-high-conviction-healthcare-winners-for-fy25?utm_medium=email&utm_campaign=Trending%20On%20Livewire%20-%20Friday%2012%20July%202024&utm_content=Trending%20On%20Livewire%20-%20Friday%2012%20July%202024+CID_5cd9984a7ff071ed3 66430d474f007f1&utm_source=campaign%20monitor&utm_term=WATCH%20%20READ%20%20LISTEN

[Panda-NZ-]

Wieight loss drugs found to reduce dementia risk by half alongside treating addiction.

https://www.investors.com/news/technology/novo-nordisk-stock-semaglutide-weight-loss-drug-dementia-risk/

They do seem to be cure-alls even without those bonuses (weight is a major contributing factor to many diseases, aside from age). I think they are charging far less than they "could" for these drugs. Happy investor in eli lilly rather than restricting myself to NZ companies.

[Valuegrowth]

Getting extremely overvalued in my opinion but heck its a big blue chip so no worries

But need to keep an eye on that squiggly line on the chartI agree. Even though it’s a quality company It has become one of the most overvalued stocks in the market. ROE is also not that impressive. It seems growth investors are ready to accept high pe ratio over 130. For me it’s scary. Other reason to stay their stock prices high is because of strong institutional backing.

[kiora]

Weight loss drugs ?

"Despite their best efforts, 80% of people who lose weight regain itand many end up heavier within 5 years. Why? Our bodies fight back, revving up hunger while slowing metabolism after weight loss. In ongoing obesity discussions, ghrelin is in the spotlight as the "hunger hormone" playing a crucial role in driving appetite and facilitating weight gain. "

https://www.medscape.com/viewarticle/ghrelin-paradox-unlocking-new-avenues-obesity-management-2024a1000bco?ecd=mkm_ret_240714_mscpmrk_endo_obesi ty_etid6666563&uac=426896AZ&impID=6666563

[kiora]

I've gone back to calculate compounding returns from FPH since when it listed in 2001

From what records I have it appears to be 12% compounding for 23 years if all dividends where reinvested
Any other offers?

So capital is 12.4 x initial investment

I was expecting 15% compounding but probably better than a good many NZX listed shares?

[Panda-NZ-]

Weight loss drugs ?

"Despite their best efforts, 80% of people who lose weight regain itand many end up heavier within 5 years. Why? Our bodies fight back, revving up hunger while slowing metabolism after weight loss. In ongoing obesity discussions, ghrelin is in the spotlight as the "hunger hormone" playing a crucial role in driving appetite and facilitating weight gain. "

https://www.medscape.com/viewarticle/ghrelin-paradox-unlocking-new-avenues-obesity-management-2024a1000bco?ecd=mkm_ret_240714_mscpmrk_endo_obesi ty_etid6666563&uac=426896AZ&impID=6666563

Hence why these drugs need to be taken like a netflix subscription (good profits).

Pharma isn't in the business of cures unless it's a $1m per treatment gene therapy.

[alokdhir]

Hence why these drugs need to be taken like a netflix subscription (good profits).

Pharma isn't in the business of cures unless it's a $1m per treatment gene therapy.

U forget how much negative the world mindset has become towards Pharma and its chemical products ...all are very vary of their motives and products ...all their products have very bad side effects ....people were ready to risk death but use covid vaccines ....Weight loss drugs and their benefits will make news now ...paid promotions etc and what not ...but soon media will be full of what happens next ...just wait for it !!!

[lissica]

U forget how much negative the world mindset has become towards Pharma and its chemical products ...all are very vary of their motives and products ...all their products have very bad side effects ....people were ready to risk death but use covid vaccines ....Weight loss drugs and their benefits will make news now ...paid promotions etc and what not ...but soon media will be full of what happens next ...just wait for it !!!


The GLP1 agonists don't come cheap. It will be the educated and wealthy who have access, not generally the covid vaccine resistant/hesitant.

[Panda-NZ-]

Even the poor though cost the US alot in terms of diabetes and heart issues in the emergency room.

Fully funded for everyone who has a prescription would result in significant taxpayer savings. But you know, america is america.

[lissica]

Weight loss drugs ?

"Despite their best efforts, 80% of people who lose weight regain itand many end up heavier within 5 years. Why? Our bodies fight back, revving up hunger while slowing metabolism after weight loss. In ongoing obesity discussions, ghrelin is in the spotlight as the "hunger hormone" playing a crucial role in driving appetite and facilitating weight gain. "

https://www.medscape.com/viewarticle/ghrelin-paradox-unlocking-new-avenues-obesity-management-2024a1000bco?ecd=mkm_ret_240714_mscpmrk_endo_obesi ty_etid6666563&uac=426896AZ&impID=6666563

Obesity is a chronic illness, no different to diabetes, which these drugs also treat.

You don't stop medication just because the diabetes is under control.

[Panda-NZ-]

Obesity could be removed as an issue in (all?) developed and some middle income countries.

While America stands out with obese people plodding along because insurance deductibles, exclusions and lack of coverage.

[kiora]

Livewire plugging their sleep apnea again

"A MID-CAP STOCK DUE FOR A RE-RATE
ResMed (ASX: RMD)
Auscap’s thesis for this founder-led business, which sells CPAP (continual positive airway pressure) devices to sufferers of obstructive sleep apnoea (OSA), is built around ResMed’s dominance within its sector. Mumford emphasises its EPS has grown by 15% per annum for a decade, alongside a ROE of more than 20%.

He notes the large selloff of the share price in the last year – and again in recent weeks - in the wake of the perceived potential impact of GLP-1 drugs.

“Having spoken to many industry participants, we think the concerns are overblown,” Mumford says.
Reasons for this include potential side-effects of GLP-1s, treatment costs, and patient adherence.

“Feedback suggests that ResMed remains the strongly preferred CPAP standard of care, with physicians tending to view GLP-1s as an adjunctive OSA therapy to CPAP and demand trends for the CPAP sector remain extremely strong,” says Mumford.

“It also appears that the sudden focus on weight and health that has arisen from the GLP-1 fervour has substantially increased awareness of OSA, a particularly under-diagnosed condition, which is increasing the number of patients looking for a solution.”

He also refers to ResMed estimates that the potential global OSA market is approximately 1 billion people, with just 23.5 million people connected to ResMed devices as of FY23.

“ResMed is currently trading on a forward price to earnings multiple that is a significant discount to where it has traded historically, and even more so relative to the broader market, which we think is a great opportunity to buy in at an attractive price for long term investors,” Mumford says."

https://www.livewiremarkets.com/wires/asx-mid-caps-poised-to-outperform-and-1-stock-auscap-says-is-due-a-re-rate?utm_medium=email&utm_campaign=Trending%20on%20Livewire%20-%20Thursday%2018%20July%202024&utm_content=Trending%20on%20Livewire%20-%20Thursday%2018%20July%202024+CID_ae24a061b812f48 0e2dc384df6c37e04&utm_source=campaign%20monitor&utm_term=READ%20MORE

[kiora]

"New Samsung watches that detect sleep apnea should be good for sales"

[winner69]

Todays Market Report ….. At home, market leader Fisher and Paykel Healthcare was up 50c to $32.85 –it was last at that level in December 202

That’s pretty cool eh

Wonder if it’ll get to 35 bucks this month?

[kiora]

Another respiratory pandemic around the corner ???
Or just able to perform more ops in hospital now???

[winner69]

Things going well for FPH

That’ll allay any fear that F25 might just be an ordinary yesr

Shares over $37 bucks soon

http://nzx-prod-s7fsd7f98s.s3-website-ap-southeast-2.amazonaws.com/attachments/FPH/436696/425433.pdf🔜

[Sideshow Bob]

https://www.nzx.com/announcements/436696

Fisher & Paykel Healthcare provides first half guidance for the 2025 financial year and updates full year outlook

Auckland, New Zealand, 23 August 2024 – Fisher & Paykel Healthcare Corporation Limited announced that it has provided guidance for the first half of the 2025 financial year, which ends 30 September 2024, and updated its guidance for the full 2025 financial year.

“The year to date has begun strongly across all products and regions,” said Managing Director and CEO Lewis Gradon. “In the Hospital product group, contributions include ongoing change in clinical practice, and a good response to new product introductions. In addition, early indications are that the year to date includes a relatively high hospital census during the period in both the Northern and Southern Hemispheres as Northern Hemisphere seasonal hospitalisations persisted into the beginning of this current financial year and hospitals have returned to more normalised staffing and capacity.

“It is also pleasing to see the progress we are making with our gross margin improvement initiatives as we return to our usual practice of working on efficiency and continuous improvement activities.”

At 31 July exchange rates*, guidance assumptions for the first half of the 2025 financial year include a continuation of the current trading environment and result in revenue in the range of approximately $940 million to $950 million, and net profit after tax in the range of approximately $150 million to $160 million. At the midpoints of first half guidance, this would equate to 18% growth in reported operating revenue and 44% growth in reported net profit after tax, compared to the first half of the 2024 financial year.

Outlook for the 2025 financial year
The full year guidance previously provided in May was for operating revenue to be in the range of approximately $1.9 billion to $2.0 billion and net profit after tax to be in the range of approximately $310 million to $360 million.

At 31 July exchange rates*, the company continues to expect full year operating revenue to be in the range of approximately $1.9 billion to $2.0 billion and now expects full year net profit after tax to be in the range of approximately $320 million to $370 million.

“We expect the remainder of the financial year for our Hospital product group to have similar underlying contributions from changes to clinical practice and new product introductions. We have not changed our view on the revenue guidance range for the full year due to the additional and variable impact of Northern Hemisphere seasonal hospitalisation rates, which historically occur towards the end of our second half.

“In our Homecare product group, the new masks we have introduced are performing well, and we think this will continue to be an underlying driver into our second half.

“Our hospital products are market leaders, our masks for treating obstructive sleep apnea are getting positive reviews and we have expanding opportunities in anesthesia and surgery. We are in a strong position to achieve our long-term revenue aspirations,” concluded Mr Gradon.

[kiora]

"We are in a strong position to achieve our long-term revenue aspirations,” concluded Mr Gradon."

ONWARDS & upwards

So predictable.

You said it Winner.Do you still hold???

[winner69]

"We are in a strong position to achieve our long-term revenue aspirations,” concluded Mr Gradon."

ONWARDS & upwards

So predictable.

You said it Winner.Do you still hold???

Yep and loving the action today

First of a few upgrades I reckon …so $40 by Christmas on cards

[limmy]

Yep and loving the action today

First of a few upgrades I reckon …so $40 by Christmas on cards
This sounds good to me.

[alokdhir]

Seeing only 5 out of TOP 50 having FPH as pick in competition makes me wonder that we as a group dont fully understand its SP dynamics ...we tend to be simplistic comparing p/e with TRA or TWR etc while completely forgetting its intrinsic value ...its super wide moat and its very valuable IPs ...imo it will be better to price this company on replacement cost. metrics then pure simple financial metrics of eps etc .

I fully remember when in May 22 Hyperion Asset management from OZ started lapping up FPH while it diving down below $ 20 ...our Gurus or most were busy churning out ever lower SP based on eps etc ....now it has come full circle ...ONLY stock which has recovered almost fully to Covid highs as it seems Covid helped with find new markets and loyal customers ....lows were blamed on Covid rush going away and our leaders looking for $ 10-$ 15 ahead . But management was right when they were saying Covid will help them on long term basis ...Aussies believed but not anyone here or NZ brokerages etc .

Fisher funds took lot of flak for not taking advantage of FPH covid highs ...but they held on and now enjoying the run and long term growth ahead ...kudos to KFL having FPH as their largest holding ...its easy to replicate their portfolio but not easy to have insights like them about the worth of the stocks

One great company ie FPH has done full circle of covid high / low and now back ...similarly MFT will do ahead I reckon ....FPH had a headstart in Covid rush cycle !!